DK3149025T3 - Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf - Google Patents

Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf Download PDF

Info

Publication number
DK3149025T3
DK3149025T3 DK15796259.8T DK15796259T DK3149025T3 DK 3149025 T3 DK3149025 T3 DK 3149025T3 DK 15796259 T DK15796259 T DK 15796259T DK 3149025 T3 DK3149025 T3 DK 3149025T3
Authority
DK
Denmark
Prior art keywords
producing
methods
cell penetrating
penetrating peptides
peptides
Prior art date
Application number
DK15796259.8T
Other languages
English (en)
Inventor
Dehua Pei
Ziqing Qian
Original Assignee
Entrada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entrada Therapeutics Inc filed Critical Entrada Therapeutics Inc
Application granted granted Critical
Publication of DK3149025T3 publication Critical patent/DK3149025T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK15796259.8T 2014-05-21 2015-05-21 Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf DK3149025T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462001535P 2014-05-21 2014-05-21
US201562158351P 2015-05-07 2015-05-07
PCT/US2015/032043 WO2015179691A2 (en) 2014-05-21 2015-05-21 Cell penetrating peptides and methods of making and using thereof

Publications (1)

Publication Number Publication Date
DK3149025T3 true DK3149025T3 (da) 2019-07-22

Family

ID=54554977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15796259.8T DK3149025T3 (da) 2014-05-21 2015-05-21 Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf

Country Status (17)

Country Link
US (1) US10626147B2 (da)
EP (2) EP3149025B1 (da)
JP (2) JP6807831B2 (da)
CN (2) CN106852146B (da)
CA (1) CA2949705A1 (da)
CY (1) CY1121953T1 (da)
DK (1) DK3149025T3 (da)
ES (1) ES2739613T3 (da)
HK (1) HK1232239A1 (da)
HR (1) HRP20191254T1 (da)
HU (1) HUE045872T2 (da)
LT (1) LT3149025T (da)
PL (1) PL3149025T3 (da)
PT (1) PT3149025T (da)
RS (1) RS59119B1 (da)
SI (1) SI3149025T1 (da)
WO (1) WO2015179691A2 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3149025T3 (pl) * 2014-05-21 2019-11-29 Entrada Therapeutics Inc Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania
US10815276B2 (en) * 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11351222B2 (en) 2016-11-09 2022-06-07 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
WO2018098282A2 (en) * 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
EP3544623A4 (en) * 2016-11-22 2021-06-09 Ohio State Innovation Foundation PEPTIDIC SEQUENCES PENETRATING INTO CELLS
US20190389907A1 (en) * 2016-12-23 2019-12-26 Bicycletx Limited Peptide ligands for binding to mt1-mmp
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
JP2020529427A (ja) 2017-08-04 2020-10-08 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN108070025B (zh) * 2017-10-24 2019-11-19 中山大学附属口腔医院 一种细胞穿透肽和细胞穿透肽复合物及二者的应用
WO2019084528A1 (en) * 2017-10-27 2019-05-02 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR INTRACELLULAR ADMINISTRATION OF STAPLED PEPTIDES
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019148195A2 (en) * 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
TW201945014A (zh) 2018-02-22 2019-12-01 美商安卓達治療股份有限公司 用於治療粒線體性神經胃腸腦病變之組合物及方法
WO2019217682A1 (en) * 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
EP3817776A4 (en) * 2018-07-02 2022-11-30 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR INTRACELLULAR RELEASE OF NUCLEIC ACIDS
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
GB201900530D0 (en) * 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
CA3137095A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN115135665A (zh) * 2019-12-30 2022-09-30 俄亥俄州国家创新基金会 包含细胞穿透肽的环状蛋白
CN113105554B (zh) * 2020-01-13 2022-07-26 广东泰禾医药科技有限公司 一种抗肿瘤融合蛋白及其制法和应用
CA3206148A1 (en) 2021-01-24 2022-07-28 Michael David FORREST Therapeutic modifiers of the reverse mode of atp synthase
WO2022241408A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating tissue distribution of intracellular therapeutics
JP2024519601A (ja) * 2021-03-31 2024-05-20 エントラーダ セラピューティクス，インコーポレイティド 環状細胞透過性ペプチド
US20240247259A1 (en) * 2021-05-10 2024-07-25 Entrada Therapeutics, Inc. Compositions and methods for modulating gene expression
EP4337676A1 (en) * 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
WO2023034818A1 (en) * 2021-09-01 2023-03-09 Entrada Therapeutics, Inc. Compositions and methods for skipping exon 45 in duchenne muscular dystrophy
MX2024002640A (es) * 2021-09-01 2024-07-19 Entrada Therapeutics Inc Compuestos y metodos para salto de exon 44 en la distrofia muscular de duchenne.
WO2023081893A1 (en) * 2021-11-08 2023-05-11 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides
WO2023178327A1 (en) * 2022-03-17 2023-09-21 Ohio State Innovation Foundation Membrane translocation domains and uses thereof
WO2023205451A1 (en) * 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965536A (en) 1993-12-15 1999-10-12 Board Of Regents, The University Of Texas System Methods of inhibiting CXC intercrine molecules
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US6110889A (en) 1996-06-14 2000-08-29 Board Of Regents, The University Of Texas System Peptide tumor cell growth inhibitors
JP3791981B2 (ja) 1996-10-15 2006-06-28 森永乳業株式会社 ペプチド誘導体及び抗真菌剤
US6251854B1 (en) 1997-03-20 2001-06-26 Mauricio Montal N-methyl-d-aspartate receptor channel blockers and method for identifying such
CA2224066A1 (en) 1997-10-24 1999-04-24 Universite D'ottawa/ University Of Ottawa Peptides as analgesics
US6388054B1 (en) 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
WO2000032235A1 (de) 1998-11-26 2000-06-08 Pentapharm Ag Transportsystemkonjugate
MXPA01011001A (es) 1999-04-30 2003-06-24 Slil Biomedical Corp Quinonas novedosas como terapias para enfermedades.
EP1177197B1 (en) 1999-04-30 2006-08-09 Cellgate, Inc. Polyamines and their use in therapy
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
EP1574507A3 (en) 1999-04-30 2005-10-26 SLIL Biomedical Corporation Furo- and pyrano-naphthoquinones and their use in the treatment of cancer
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
BR0010700A (pt) 1999-04-30 2002-02-13 Slil Biomedical Corp Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata
CA2376375C (en) 1999-06-05 2011-07-12 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AU7814301A (en) 2000-08-02 2002-02-13 Slil Biomedical Corp Cyclic polyamine compounds for cancer therapy
US20030072715A1 (en) 2000-08-02 2003-04-17 Benjamin Frydman Cyclic polyamine compounds for cancer therapy
EP1345956A2 (en) 2000-10-13 2003-09-24 University of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US20030167129A1 (en) 2000-10-27 2003-09-04 Nestor John J. Binding compounds and methods for identifying binding compounds
WO2002057313A2 (en) 2000-10-27 2002-07-25 Consensus Pharmaceuticals, Inc. Receptor-binding compounds and methods for identifying them
AU2002235126A1 (en) 2000-11-08 2002-05-21 Slil Biomedical Corporation Novel polyamine analog-amino acid conjugates useful as anticancer agents
JP2005508832A (ja) 2001-02-16 2005-04-07 セルゲイト， インコーポレイテッド 間隔を開けてアルギニン部分を含むトランスポーター
JP2004535392A (ja) 2001-05-04 2004-11-25 ザ スクリプス リサーチ インスティチュート 抗菌ペプチドおよび組成物
MXPA04001142A (es) 2001-08-03 2004-09-13 Univ Leland Stanford Junior Sintesis bidireccional de agentes de transporte de oligoguanidina.
JP2005506354A (ja) 2001-10-16 2005-03-03 スリル バイオメディカル コーポレイション 癌治療のためのオリゴアミン化合物およびその誘導体
AU2002346498A1 (en) 2001-11-30 2003-06-17 Applera Corporation Thermus brockianus nucleic acid polymerases
CA2469354A1 (en) 2001-12-07 2003-06-19 Slil Biomedical Corporation Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
CA2469336C (en) 2001-12-11 2013-06-11 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
PT1483290E (pt) 2002-01-17 2008-09-19 Takeda Pharmaceutical Peptídeos e peptidomiméticos possuindo actividade antiproliferativa e/ou que aumentam os agentes ou tratamentos de danificação dos ácidos nucleicos
FR2836474B1 (fr) 2002-02-22 2004-12-24 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique
WO2003092632A2 (en) 2002-05-06 2003-11-13 The Scripps Research Institute Cyclic peptide anti-cancer agents and methods
AU2003241384A1 (en) 2002-05-06 2003-11-17 The Scripps Research Institute Cyclic peptide anti-viral agents and methods
WO2004002991A1 (en) 2002-06-26 2004-01-08 Cellgate, Inc. Porphyrin-polyamine conjugates for cancer therapy
US20040192665A1 (en) 2002-08-02 2004-09-30 Slil Biomedical Corporation Conjugates of porphyrin compounds with chemotherapeutic agents
US20060128614A1 (en) 2002-09-20 2006-06-15 Jya-Wei Cheng Antimicrobial peptides with reduced hemolysis and methods of their use
WO2004050685A2 (en) 2002-11-29 2004-06-17 Adaptive Therapeutics, Inc. Antifungal therapeutic agents
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
JP2007526316A (ja) 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
MX2007004030A (es) 2004-10-04 2008-01-14 Cellgate Inc Analogos de poliamina como agentes terapeuticos para enfermedades oculares.
WO2006086773A2 (en) 2005-02-11 2006-08-17 Cellgate, Inc. Polyamine analogs as modulators of cell migration and cell motility
WO2007040535A1 (en) 2005-10-03 2007-04-12 Cellgate, Inc. Use of polyamine analogs for treatment and prevention of intestinal polyps
WO2007055578A1 (en) 2005-11-11 2007-05-18 Leids Universitair Medisch Centrum Cyclic antimicrobial peptides derived from lactoferrin
US20080090760A2 (en) 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
WO2007072037A1 (en) 2005-12-22 2007-06-28 Novabiotics Limited Cyclic antimicrobial peptides
US9181303B2 (en) 2005-12-22 2015-11-10 Novabiotics Limited Treatment of bacterial infections with cyclic antimicrobial peptides
EP1991560B1 (en) * 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
KR20090041360A (ko) 2006-02-27 2009-04-28 테크니쉐 유니베르시테트 뮌헨 암 영상화 및 치료방법
WO2007106554A2 (en) 2006-03-14 2007-09-20 Progen Pharmaceuticals, Inc. Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
WO2007108749A1 (en) 2006-03-20 2007-09-27 Cepep Iii Ab Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents
WO2007111993A2 (en) 2006-03-22 2007-10-04 Cellgate, Inc. Polyamine analogs as therapeutic agents for skin diseases
WO2008077194A1 (en) 2006-12-22 2008-07-03 Xenome Ltd Receptor agonists
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
EP3320923B1 (en) 2008-01-18 2022-04-06 Visen Medical, Inc. Fluorescent imaging agents
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
US8629112B2 (en) 2010-02-05 2014-01-14 Frank Otto Gombert Template-fixed peptidomimetics with CXCR7 modulating activity
WO2011095218A1 (en) 2010-02-05 2011-08-11 Polyphor Ag Template-fixed pep tidomime tics with cxcr7 modulating activity
WO2011126010A1 (ja) * 2010-04-06 2011-10-13 三菱化学株式会社 癌細胞選択的膜透過性ペプチドおよびその利用
JP2012131743A (ja) * 2010-12-22 2012-07-12 Kyoto Univ 腫瘍集積型抗癌剤
US9744191B2 (en) 2012-03-19 2017-08-29 Yale University Antimicrobial compositions and methods
WO2014053882A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US20150038671A1 (en) 2013-05-30 2015-02-05 Keykavous Parang Efficient Synthesis of CN2097 and RC7 and Their Analogs
US10736932B2 (en) 2014-05-20 2020-08-11 Ohio State Innovation Foundation Small molecule Ras inhibitors
PL3149025T3 (pl) * 2014-05-21 2019-11-29 Entrada Therapeutics Inc Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
CA2955057A1 (en) 2014-07-11 2016-01-14 C3 Jian, Inc. Targeting peptides that bind s. mutans, constructs comprising such peptides and uses thereof
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US10351599B2 (en) 2014-09-19 2019-07-16 Tensive Controls, Inc. Anti-microbial peptides
JP2016065018A (ja) 2014-09-25 2016-04-28 国立大学法人京都大学 Ｃｘｃｒ７結合剤およびｃｘｃｒ７結合剤を含有する医薬組成物
CN105440105B (zh) 2015-12-17 2018-11-27 倪京满 一种具有高稳定性及抗耐药活性的组合抗菌肽的制备和应用

Also Published As

Publication number Publication date
LT3149025T (lt) 2019-09-25
CN106852146B (zh) 2021-08-13
CN106852146A (zh) 2017-06-13
PL3149025T3 (pl) 2019-11-29
US10626147B2 (en) 2020-04-21
JP6807831B2 (ja) 2021-01-06
CA2949705A1 (en) 2015-11-26
WO2015179691A9 (en) 2016-03-31
EP3149025B1 (en) 2019-06-26
EP3149025A2 (en) 2017-04-05
WO2015179691A2 (en) 2015-11-26
WO2015179691A3 (en) 2016-02-25
HK1232239A1 (zh) 2018-01-05
HUE045872T2 (hu) 2020-01-28
RS59119B1 (sr) 2019-09-30
ES2739613T3 (es) 2020-02-03
SI3149025T1 (sl) 2019-09-30
EP3613426A9 (en) 2023-05-24
EP3149025A4 (en) 2018-02-21
PT3149025T (pt) 2019-08-01
US20170190743A1 (en) 2017-07-06
JP2017519041A (ja) 2017-07-13
HRP20191254T1 (hr) 2019-10-18
JP2020169170A (ja) 2020-10-15
JP7530203B2 (ja) 2024-08-07
EP3613426A1 (en) 2020-02-26
CY1121953T1 (el) 2020-10-14
CN113861268A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
DK3149025T3 (da) Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf
DK3215601T3 (da) Fremgangsmåder til transduktion og celleforarbejdning
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3224603T3 (da) Nordning og fremgangsmåde til materialekarakteristik
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3201351T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3339479T3 (da) Elektrolyseindretning og elektrolysefremgangsmåde
DK3265947T3 (da) Fremgangsmåde og system til kryptering
DK3221912T3 (da) Hidtil ukendte polymerer og fremgangsmåder til fremstilling heraf
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3105335T3 (da) Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
DK3213065T3 (da) System og fremgangsmåder til todimensionel rplc-sfc-kromatografi
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3090416T3 (da) Fremgangsmåde og system til overvågning
DK3368663T3 (da) Virusfri cellelinjer og fremgangsmåder til opnåelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3230795T3 (da) Prægelak og fremgangsmåde til prægning
DK3101760T3 (da) Opladningsfremgangsmåde og system
DK3240892T3 (da) Rpe-cellepopulationer og fremgangsmåder til dannelse deraf